Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company based in Hanover, Germany, developing non-coding RNA (ncRNA)-based therapeutics to prevent, repair and reverse diseases of the heart. Its lead candidate, CDR132L, is a highly stable oligonucleotide ncRNA inhibitor directed at micro‑RNA‑132 and has completed Phase 1b with a favorable safety profile and beneficial cardiac effects in 28 heart-failure patients. Cardior is initiating a Phase II trial of CDR132L with the aim of demonstrating clinical proof-of-concept as a disease-modifying therapy. The company’s approach seeks to block aberrant micro-RNA-132 levels to address cardiac hypertrophy, fibrosis, impaired contractility and reduced vascularization. Its pipeline addresses large cardiac indications as well as rare diseases such as hypertrophic and dilated cardiomyopathies. The company intends to use new funding to advance late-stage development of the lead program and expand its earlier-stage pipeline. Cardior Pharmaceuticals is a spin-off from Hannover Medical School advancing proprietary non-coding RNA technology to predict and treat heart failure. The company targets specific non-coding RNAs that simultaneously control cardiac growth and calcium handling/contractility of cardiomyocytes. Targeting these RNAs has been shown to reverse maladaptive cardiac remodeling and restore normal cardiac function. Cardior is led by CEO Dr. Claudia Ulbrich and CSO Prof. Thomas Thum. The company will use new funding to continue advancing its therapeutic programs.

Total raised

$92M

Funding rounds

2

Latest round

Series B

Latest activity

Aug 2021